BibSonomy :: publication :: The Meningitis Vaccine Project

The Meningitis Vaccine Project

F Marc LaForce, Kader Konde, Simonetta Viviani, and Marie-Pierre Préziosi. Vaccine (September 2007)PMID: 17521780.

Abstract

Epidemic meningococcal meningitis is an important public health problem in {sub-Saharan} Africa. Current control measures rely on reactive immunizations with polysaccharide {(PS)} vaccines that do not induce herd immunity and are of limited effectiveness in those under 2 years of age. Conversely, polysaccharide conjugate vaccines are effective in infants and have consistently shown an important effect on decreasing carriage, two characteristics that facilitate disease control. In 2001 the Meningitis Vaccine Project {(MVP)} was created as a partnership between {PATH} and the World Health Organization {(WHO)} with the goal of eliminating meningococcal epidemics in Africa through the development, licensure, introduction, and widespread use of conjugate meningococcal vaccines. Since group A Neisseria meningitidis {(N.} meningitidis) is the dominant pathogen causing epidemic meningitis in Africa {MVP} is developing an affordable {(US\$} 0.40 per dose) meningococcal A {(Men} A) conjugate vaccine through an innovative international partnership that saw transfer of a conjugation and fermentation technology to a developing country vaccine manufacturer. A Phase 1 study of the vaccine in India has shown that the product is safe and immunogenic. Phase 2 studies have begun in Africa, and a large demonstration study of the conjugate vaccine is envisioned for 2008-2009. After extensive consultations with African public health officials a vaccine introduction plan has been developed that includes introduction of the Men A conjugate vaccine into standard Expanded Programme on Immunization {(EPI)} schedules but also emphasizes mass vaccination of 1-29 years old to induce herd immunity, a strategy that has been shown to be highly effective when the meningococcal C {(Men} C) conjugate vaccine was introduced in several European countries. The {MVP} model is a clear example of the usefulness of a "push mechanism" to finance the development of a needed vaccine for the developing world.

Links and resources

DOI:10.1016/j.vaccine.2007.04.049
URL:http://www.ncbi.nlm.nih.gov/pubmed/17521780
BibTeX key:laforce_meningitis_2007
internal link:
?
You can use this internal link to create references to this post in your discussions. Just copy this internal link and paste it in your discussion text.
search on:

Comments or reviews  
(0)

There is no review or comment yet. You can write one!

Tags

  • Last update 3 years and 5 months ago.
  • Created 3 years and 5 months ago.

Cite this publication